Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a Phase 2 basket trial to evaluate the safety, efficacy, and pharmacokinetics of ebribafusp for the treatment of rare complement-mediated kidney diseases, including IgA nephropathy (IgAN), lupus nephritis (LN), and C3 glomerulopathy (C3G). Ebribafusp (previously referred to as AKB-097 and ADX-097) is an anti-C3d factor H fusion protein designed to inhibit complement activation in tissues without inhibiting the complement system in the blood.